Install
Local Connecticut search and resources
Built for Connecticut users
4Connecticut is a search engine created specifically to help people find Connecticut-related websites, businesses, news, and resources more efficiently. It combines multiple indexes, relevance signals tuned for the state, and curated content to surface local government pages, community organizations, regional news, and Connecticut businesses. Use 4Connecticut to search with local context and get results that general search engines may miss. Part of the 4SEARCH network of topic specific search engines.
Latest Articles
Stamford marathon revives historic 1896 race
18+ hour, 20+ min ago (378+ words) McKenna Duff and AJ Schrag discuss recreating America's first marathon in Stamford, Connecticut, and inspiring the community through running. Martin Newman killed Gracie-Ann, 4, and Jayden-Lee, 3, after crashing his van into a car on the M4. Kelly O'Shea felt there was no…...
Bristol Myers' Phase 3 Trial Of Admilparant In Idiopathic Pulmonary Fibrosis Met Primary Endpoint
1+ day, 20+ min ago (173+ words) Bristol Myers Squibb (BMY), a biopharmaceutical company, announced Monday the topline results from its pivotal Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF). Admilparant is a potential first-in-class, orally administered lysophosphatidic acid receptor 1 (LPA1) antagonist. The trial…...
SpaceX rocket and ISS could appear over Connecticut at the same time Tuesday. Here's when to see it
12+ hour, 32+ min ago (258+ words) As Connecticut drivers inch through Tuesday morning traffic, two very different vehicles could be racing overhead: a SpaceX rocket climbing toward orbit and the International Space Station sweeping across the dawn sky. Neither is likely to make it to work…...
Bristol Myers falls 3% despite positive cancer drug trial results
20+ hour, 32+ min ago (202+ words) Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. RYZ101 is a targeted radiopharmaceutical therapy developed by…...
Bristol Myers Squibb (BMY) drops 4.3%: what the slide means for dividend investors
23+ hour, 18+ min ago (306+ words) As seen on the 24/7 Wall St. homepage on October 12, 2026. A 4.29% slide to $57.23 is an outsized single session for a $117 billion pharma name that usually trades like a bond proxy. Dividend buyers watching for an entry get a cheaper one today....
Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets Primary Endpoint
1+ day, 1+ hour ago (187+ words) Bristol Myers Squibb (BMY) said Monday that an interim analysis of a phase 3 trial evaluating RayzeBio's radiopharmaceutical therapy RYZ101 met its primary endpoint. Bristol Myers... Oops, something went wrong U.S. markets close in 3h 40m Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets…...
Bristol down as Street reacts to admilparant results in IPF
21+ hour, 29+ min ago (60+ words) Bristol Myers slips after mixed phase 3 admilparant IPF results; analysts weigh dose-response concerns and approval odds. Read more here. After opening Monday's trading session initially higher, Bristol Myers Squibb (BMY) shares are now down ~3% as the Street more fully digests…...
Bristol Myers dips on ‘confounding’ lung drug results
14+ hour, 20+ min ago (360+ words) Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects. Admilparant is the furthest along among a class of idiopathic pulmonary fibrosis, or…...
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
19+ hour, 42+ min ago (55+ words) Individuals currently enrolled will continue to receive care consistent with the study protocol, and participants will be followed for overall survival. About Bristol Myers Squibb: Transforming Patients’ Lives Through Science KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA SOURCE: Bristol Myers…...
Bristol-Myers Squibb Announces Positive Topline Data From RYZ101 Study, Stock Up In Pre-Market
1+ day, 3+ min ago (125+ words) Conducted by the company's subsidiary RayzeBio, Inc., the study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review. Safety results were also consistent with the known RYZ101 safety profile. Earlier,…...